Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

    NEXT STORY
    Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    PREV STORY
    NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeyondSpring Pharmaceuticals’ Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC

    NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals Inc., a clinical stage ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch

    author_avatar
    NASDAQ Market News

    Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone

    CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") ...

    author_avatar
    NASDAQ Market News